Roche Accelerates Drug Discovery with Quantum Simulation
Molecular simulation for drug discovery
Overview
Roche has partnered with Cambridge Quantum Computing (now Quantinuum) to explore quantum computing for molecular simulation in drug discovery. The collaboration focuses on simulating molecular interactions that are intractable for classical computers, potentially reducing drug discovery timelines by years.
The project targets quantum chemistry calculations for protein-ligand interactions relevant to oncology and infectious disease research.
Vendor
Quantinuum
Quantum Modality
Trapped Ion
Benefits
Exponentially faster molecular simulations, enabling discovery of new drug candidates and reducing clinical trial failure rates through better computational screening.
ROI Metrics
Potential to reduce drug discovery timelines by 30-50%. Significant cost savings from improved pre-clinical screening accuracy.
Architecture
Quantum simulation pipeline using Quantinuum's H-series trapped-ion quantum computers, with classical pre/post-processing for molecular structure preparation and analysis.
Migration Notes
Start with quantum chemistry libraries (Qiskit Nature, PennyLane). Use NISQ-era variational algorithms (VQE) for near-term molecular simulations. Scale to fault-tolerant algorithms as hardware improves.
Security Considerations
Proprietary molecular data must be protected. Use quantum-safe encryption for clinical trial data.
Implementation Roadmap
Phase 1: VQE benchmarking on small molecules (complete). Phase 2: Protein fragment simulation (ongoing). Phase 3: Full protein-ligand simulation (2028+).